We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.
- Authors
Tanase, Daniela Maria; Gosav, Evelina Maria; Petrov, Daniela; Jucan, Alina Ecaterina; Lacatusu, Cristina Mihaela; Floria, Mariana; Tarniceriu, Claudia Cristina; Costea, Claudia Florida; Ciocoiu, Manuela; Rezus, Ciprian
- Abstract
Non-alcoholic fatty liver disease (NAFLD) and atherosclerosis (ATS) are worldwide known diseases with increased incidence and prevalence. These two are driven and are interconnected by multiple oxidative and metabolic functions such as lipotoxicity. A gamut of evidence suggests that sphingolipids (SL), such as ceramides, account for much of the tissue damage. Although in humans they are proving to be accurate biomarkers of adverse cardiovascular disease outcomes and NAFLD progression, in rodents, pharmacological inhibition or depletion of enzymes driving de novo ceramide synthesis prevents the development of metabolic driven diseases such as diabetes, ATS, and hepatic steatosis. In this narrative review, we discuss the pathways which generate the ceramide synthesis, the potential use of circulating ceramides as novel biomarkers in the development and progression of ATS and related diseases, and their potential use as therapeutic targets in NAFDL-ATS development which can further provide new clues in this field.
- Subjects
NON-alcoholic fatty liver disease; DRUG target; CERAMIDES; FATTY liver; CARDIOVASCULAR diseases
- Publication
Diagnostics (2075-4418), 2021, Vol 11, Issue 11, p2053
- ISSN
2075-4418
- Publication type
Article
- DOI
10.3390/diagnostics11112053